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WHAT’S ALREADY KNOWN? 
The prognostic significance of histological regression in primary melanoma has been debated for 
many years. Still, no robust data is reported on the prognostic value of histological regression. 
WHAT DOES IT ADD? 
The results of this meta-analysis may be useful when looking at the histological regression in a 
melanoma to consider it as a favourable prognostic factor, probably linked to early activation of 
the host immune system against the tumour. 
 
ABSTRACT 
INTRODUCTION The prognostic significance of histological regression in primary melanoma 
has been debated for many years. We aim to review the evidence to look how histological 
regression may affect prognosis. 
METHODS. A systematic review was performed by searching in MEDLINE, Scopus, and the 
Cochrane Library from January 1st  1966, through August 1st 2015. All studies that reported HR 
or data on survival and histological regression were included. 
Primary random-effects meta-analyses were used to summarise outcome measures. 
Heterogeneity was assessed using the χ2 test and I2 statistic. To assess the potential bias of small 
studies we used funnel plots and the Begg and Mazumdar adjusted rank correlation method. 
Summary of survival outcomes were measured as Hazard Risks or Relative risk of death  at 5 
years according to the presence of  histological regression of primary melanoma.  
RESULTS 183 articles were reviewed out of 1876. 10 studies comprising 8557 patients were 
included. Patients with histological regression had a lower Relative Risk of death ( 0.772;95%CI, 
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0.612-0.973) than patients without. Examination of the funnel plot did not provide evidence of 
publication bias. 
CONCLUSION The results showed that histological regression is a protective factor for 
survival.  
 
 
 
 
INTRODUCTION 
Histological regression in melanoma has been defined as an area within the tumour in which 
neoplastic cells have disappeared or become reduced in number from the dermis (and 
occasionally from the epidermis) and have been substituted by fibrosis. This phenomenon is 
accompanied by melanophagia, new vessels and a variable inflammatory infiltrate [1,2,3]. The 
frequency of histological regression is variable in literature, but it has been reported from 10% to 
35% [4].  
Meanwhile, the prognostic significance of histological regression in primary melanoma has been 
debated for many years. Some studies reported potential poor prognosis in association with 
histological regression because the disappearance of a portion of the tumour may lead to an 
underestimation of the original Breslow thickness. Its prognostic value has often been analysed, 
although no accordance is reported in literature. Although often debated, histological regression 
never reached the status of a prognostic criterion for melanoma staging classification. 
Some studies have reported an increasing risk of developping a metastasis and consequently a 
poorer survival rate [5,6] for patients with  histological regression of primary melanoma. 
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Contrarily, other studies have shown that histological regression does not increase the risk of 
metastases [1,7] and does not negatively impact prognosis[8].  
The most important prognostic factor in intermediate and thick melanoma is sentinel lymph node 
positivity [9,10]. A recent meta-analysis on 10098 patients looking at the association between 
SLN status and histological regression have showed a lower risk of SLN metastasis in patients 
carrying this feature in their tumour (OR=0.56; 95%CI: 0.41-0.77)[11]. Results reported in 
literature on the survival role of histological regression are usually based on monocentric case 
series and are not conclusive on the significant role of histological regression. 
To review the evidence that histological regression may affect survival, we conducted a meta-
analysis of published literature to provide a more objective estimate of the mortality risk in 
patients with histological regression in primary melanoma tumours. 
 
MATERIALS AND METHODS  
We carried out this review in accordance with PRISMA (Preferred Reporting Items for 
Systematic review and Meta-Analysis guidelines) [12].  
Search Strategy, Eligibility Criteria and Study Selection 
A systematic review of original articles and abstracts analysing the survival of patients with 
histological regression of primary melanoma was performed by searching in MEDLINE, Scopus 
and Cochrane Library from January 1st 1966 till July the 1st 2015. The search strategy included 
the following keywords in various combinations: ‘‘melanoma,’’ ‘‘regression,’’ ‘‘histological 
regression”, “survival”, and “prognosis”; 1876 citations were reported in total. In addition, we 
reviewed articles and relevant reviews to locate publications missed by the database searches. 
Two authors (SR and EM) independently assessed the eligibility of studies. Any disagreement 
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was settled by consensus, including a third and fourth investigator (EF and SOA). The article 
titles and abstracts were used for initial screening, followed by review of the full text. There was 
no restriction criterion on the number of patients enrolled in the study. Only original manuscripts 
in English language were included. Searches were supplemented by scanning bibliographies of 
included articles. We excluded articles that reported no data, such as review articles and 
editorials. If duplicate data were present in separate publications, we included the publication 
with the larger amount of data or the more recent. All articles that reported survival data 
regarding histological regression in melanoma patients were eligible for inclusion. 
Data Extraction  
We used a data extraction form based on the Cochrane consumers and communication review 
group data examination template [13]. For each study selected, the following data were 
extracted: journal, year, study design, number of patients, age, gender, melanoma thickness, 
ulceration, and  histological regression. The survival data were considered as survival rate at 5 
years or HR. As studies reported different types of measurements we performed  a sensitivity 
analysis, in accordance with the current literature [14].  
 
 
Statistical analysis  
To integrate previous findings on this topic, we performed a meta-analysis of published literature 
to provide an estimation of the risk of death in melanoma patients with evidence of histological 
regression in the primary tumour. Because studies were found to be heterogeneous (I2 >30%), 
summary Rate Ratios (RRs) with corresponding 95% confidence intervals (95% CIs) were 
calculated using random-effects modelling. Publication bias was assessed through the 
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construction of a funnel plot for the primary endpoint, as well as with the Begg and Mazumdar 
adjusted rank correlation method and Egger test.  
Statistical analyses were performed using the Stata 13.0 statistical software (StataCorp, College 
Station, TX, U.S.A.). 
RESULTS 
Characteristics of Included Studies 
The initial search resulted in 1876 citations (Figure 1). The title and abstract of each retrieved 
publication was reviewed to confirm that the article included survival data regarding histological 
regression melanoma tumours. In the event that this approach was not informative, the full article 
was retrieved and further reviewed. This process resulted in the selection of 183 studies. Of 
these, 173 were eventually excluded from this analysis because they did not show clear results on 
survival and histological regression. In particular, it was not possible to differentiate the survival 
analyses (in terms of HR or survival rate) according to histological regression. 17 studies 
reported overlapping data points from other studies were also excluded. Therefore, ten 
studies[15-24] were eligible to be included in the systematic review and meta-analysis. Three of 
them reported data pooled from many centres (Table 1) [16, 21, 22]. 
In the study, 8557 patients were finally included. Survival data were described as HR in 4 studies 
[18,22,23,24]. Survival rate at 5 years was reported in 6 studies [15-17, 19-21]. Meanwhile, 
histological description of regression was reported in 9 papers [15-23]. In 3 studies, the presence 
of histological regression was significantly associated to a better prognosis [18, 20, 22], while in  
7 it was not significantly associated to survival [15-18,20,22,24]. All studies reported clinical 
data of the patients on gender and age. Among them, data on Breslow thickness, which is the 
major prognostic factor in melanoma patients, were described as mean depth in 2 studies [16, 23]  
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or as median in 1 [20]. In the remaining 7 studies [15,17-19,21,22,24], Breslow thickness was 
reported as categorical cut-off. Ulceration distribution was described in 8 out of 10  studies [15, 
18-24]. 
Outcome of Meta-analysis 
In the 10 studies included, patients with histological regression of primary melanoma had a 
lower likelihood of death (RR 0.772; 95% CI, 0.612-0.973) than patients without histological 
regression (Figure 2). Examination of the funnel plot (Figure 4) did not provide evidence of 
publication bias. Similarly, there was no evidence of such bias for the sensitivity analysis. In 
fact, it displays that the points are evenly distributed and symmetrical, thus showing absence of 
asymmetry and that the results of the study are reliable. This evidence was confirmed by the 
results of the Begg and Mazumdar test (p-value 0.37) and Egger test (p-value=0.19). When 
stratified on the main outcome of the studies, the meta-analysis of those reporting RR at 5 years 
was still significant (RR 0.722; CI, 0.535-0.975) (Supplementary figure 1), while the one of 
those reporting HR was not (HR 0.852; CI,  0.575-1.263) (Supplementary figure 2).   
Examination of the funnel plot (Supplementary Figure 3 and Supplementary Figure 4) did not 
provide evidence of publication bias 
DISCUSSION 
In this systematic review and meta-analysis including 10 studies [15-24] and more than 8500 
patients, we found that histological regression is a protective feature for survival in melanoma 
patients: melanoma patients with regression had a lower likelihood to die (RR 0.772; 95% CI, 
0.612-0.973) than patients without histological regression. 
 
Clinical significance 
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Reported data regarding the prognostic role of histological regression has hitherto been 
conflicting [5,25-27]. In the past, histological regression has traditionally been considered as a 
marker of poor prognosis, because it leads to an under-estimation of melanoma thickness [5]. 
Some studies found that histological regression in melanoma does not increase the risk of 
lymphatic metastasis therefore do not affect prognosis, while others studies reported that it is 
associated with a poor prognosis, particularly in thin melanomas [25,26].  A recent paper on a 
large setting of stage I-II patients has shown a protective role on prognosis in melanoma patients 
with histological regression(stage I-II AJCC ) [23]. At the same time, the discussion regarding 
the SLN performance in thin melanoma with regression has arrived to an answer [28]: a meta-
analysis has confirmed that histological regression is not a criterion for recommendation of 
SLNB in thin melanomas [12]. 
 
To our knowledge, the current report represents the first meta-analysis to focus on the prognostic 
value of histological regression in melanoma patients.  The majority of the studies were not able 
to define the histological regression as protective or worsening  in survival. In particular, there is 
no paper included in the study that reported a significantly negative association between 
histological  regression and survival (See fig 2). We have performed this meta-analysis to 
determine if pooling data together would allow us to achieve a final consideration. We found that 
the risk of death was significantly lower in patients with histological regression in melanoma 
tumours compared to those without.  
No robust data are reported on the prognostic value of histological regression. So far, the 
biological role of histological regression in primary melanoma has been interpreted in a 
contradictory fashion. Once histological regression has been was considered able to decrease the 
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tumour thickness, leading to a sub-staging of the Breslow thickness. On the other hand, Tumour 
regression has been described as an indicator of a tumour-directed immune response[3]. Tumour-
directed T-cell responses, however, may contribute to an improved prognosis as shown by the 
successful treatment with drugs stimulating the immune system’s responsiveness [29-33].  
As melanoma is a strong immunogenic tumour, a strong host immunological response to the 
tumour is thought to be the cause of the histological regression of the primary tumour. It would 
therefore be expected that the presence of regression would confer survival advantage.  
Nevertheless, it can be suggested that a host immunological response to the tumour could be the 
basis of regression. Further, histological regression could mirror the power of the immunologic 
system against the primary tumour and its presence should be considered prognostically 
favourable. Ma et al. [34] showed that histological regression results from a T-cell immune 
response associated with a decreased risk of nodal progression. In particular, the same authors 
described a down-regulation of the anti-tumour immunity in the positive SLN with an increase in 
regulatory T cells, compared with the negative non-sentinel node from the same nodal basin.  
 
 
Limitations 
Significant heterogeneity with respect to quality characteristics has been present among the 
studies, as confirmed by the Q statistics. The authors are conscious of heterogeneity in this study 
in terms of melanoma features (ulceration and thickness). All the included studies described 
melanoma cohorts as classically reported in literature and the large majority of them included both 
thin and thick melanomas, considering consecutive case series of patients. As suggested by the 
scientific literature [35], meta-analysis in the presence of heterogeneity is commonly performed 
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by using a random-effects model, thus we have chosen to use this statistical model to solve this 
concern. 
Furthermore, because covariance information was not consistently reported in the published 
studies, we could not adjust our pooled estimate for the confounding effects of formal meta-
regression. Thus, the reliability of summary estimates is contingent upon the quality of the 
studies pooled. Although included studies met many of the a priori quality metrics, important 
deficiencies remained.  
Another limitation that has to be acknowledged is the use of combined rate ratios, which we 
calculated from the data extracted from the selected studies. Further, due to the fact that we 
combined different types of measurements, methodological concerns may arise, leading to 
potential bias [14,36]. 
Another potential limitation is that the included studies may have had different definitions of 
histological regression. As the definition of this feature is sometimes defined from a pathological 
point of view, the subjectivity of pathology could influence the final report of each melanoma. 
Despite this, the modality of evaluation of  histological regression has been described in the same 
modality in 9 papers out of 10: only Ito and colleagues [24] did not describe how histological 
regression was evaluated. Indeed, we cannot guarantee the quality of superimposable data. In line 
with International Consensus guidance, further studies are encouraged to utilise more reproducible 
evaluation features of histological regression, such as the percentage of the lesion regressed (etg. 
50%)[25]. Moreover, this study is limited by the fact that it included only observational studies. 
Most studies were retrospective from a single institution. Pitfalls in dermatopathology are always 
possible, but this is a common  problem of all retrospective studies in which there is not a central 
control.  In some cases, multiple reports were published overtime from the same institution and 
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considerable effort was expended in an attempt to identify and utilise the most suitable report. It 
is possible, however, that some patients were not included when trying to avoid duplicates in 
consecutive studies reported by the same group. Nevertheless, based on the size of the study, it is 
unlikely that missing these cases would have significantly affected the results. These limitations 
underscore the need for standardised reporting of relevant covariates in future observational 
studies. From a methodological perspective, histological regression needs a worldwide consensus 
regarding its definition in order to further analyse this intriguing feature. All other prognostic 
factors should also be collected accurately. It has also been recommended that two pathologist 
separately assess the histological regression in primary melanoma specimens and that a high 
inter-observer agreement is achieved.  
  
Conclusion 
The results of this meta-analysis may be useful when looking at the histological regression in a 
melanoma to consider it as a favourable prognostic factor, probably linked to early activation of 
the host immune system against the tumour.   
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FIGURE TITLE:  
Figure 1. Flowchart of Article Search and Inclusion 
Figure 2. Likelihood of death  in Patients With  Melanoma with regression 
Figure 3: Funnel Plot of the Studies Included in the Meta-analysis 
 
Figure 1 supplementary : Likelihood of death  in Patients With  Melanoma with regression (data 
reported RR) 
Figure 2 supplementary Likelihood of death  in Patients With  Melanoma with regression (data 
reported HR) 
Figure 3 supplementary Funnel Plot of the Studies Included in the Meta-analysis (data reported 
RR) 
Figure 4 supplementary Funnel Plot of the Studies Included in the Meta-analysis (data reported 
HR) 
 
 
 
FIGURE LEGEND: 
 
 
Figure 2: Illustrated are the standardized Relative risk of death for the studies included in the 
meta-analysis. Patients with histologic regression of primary melanoma had a lower likelihood of 
death (RR 0.772; 95% CI, 0.612-0.973); darker dashed vertical line) than patients without 
regression. 
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Figure 3: The funnel plot displays points (each representing an included study) that are evenly 
and symmetrically distributed, thus showing the absence of study bias and suggesting that the 
results of the studies are reliable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
